vs
Century Communities, Inc.（CCS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Century Communities, Inc.的季度营收约是Revvity的1.0倍（$789.7M vs $772.1M），Revvity净利率更高（12.7% vs 3.1%，领先9.6%），Revvity同比增速更快（5.9% vs -12.6%），过去两年Revvity的营收复合增速更高（9.0% vs -12.8%）
二十世纪动画公司是美国知名动画制作工作室，原总部位于洛杉矶世纪城，与福克斯集团的租约到期后迁至伯班克华特迪士尼影城园区。该公司成立于1994年2月，现为华特迪士尼影业旗下二十世纪影业的动画制作分支，出品的动画电影由华特迪士尼影业负责全球院线发行与营销。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CCS vs RVTY — 直观对比
营收规模更大
CCS
是对方的1.0倍
$772.1M
营收增速更快
RVTY
高出18.4%
-12.6%
净利率更高
RVTY
高出9.6%
3.1%
两年增速更快
RVTY
近两年复合增速
-12.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $789.7M | $772.1M |
| 净利润 | $24.4M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 3.1% | 12.7% |
| 营收同比 | -12.6% | 5.9% |
| 净利润同比 | -38.0% | 3.9% |
| 每股收益（稀释后） | $0.88 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCSRVTY
| Q1 26 | $789.7M | — | ||
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $980.3M | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $903.2M | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.0B | $691.7M |
净利润CCSRVTY
| Q1 26 | $24.4M | — | ||
| Q4 25 | $36.0M | $98.4M | ||
| Q3 25 | $37.4M | $46.7M | ||
| Q2 25 | $34.9M | $53.9M | ||
| Q1 25 | $39.4M | $42.2M | ||
| Q4 24 | $102.7M | $94.6M | ||
| Q3 24 | $83.0M | $94.4M | ||
| Q2 24 | $83.7M | $55.4M |
毛利率CCSRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率CCSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 14.5% | ||
| Q3 25 | 4.9% | 11.7% | ||
| Q2 25 | 4.7% | 12.6% | ||
| Q1 25 | 5.8% | 10.9% | ||
| Q4 24 | 10.6% | 16.3% | ||
| Q3 24 | 9.7% | 14.3% | ||
| Q2 24 | 10.6% | 12.4% |
净利率CCSRVTY
| Q1 26 | 3.1% | — | ||
| Q4 25 | 2.9% | 12.7% | ||
| Q3 25 | 3.8% | 6.7% | ||
| Q2 25 | 3.5% | 7.5% | ||
| Q1 25 | 4.4% | 6.4% | ||
| Q4 24 | 8.1% | 13.0% | ||
| Q3 24 | 7.3% | 13.8% | ||
| Q2 24 | 8.1% | 8.0% |
每股收益（稀释后）CCSRVTY
| Q1 26 | $0.88 | — | ||
| Q4 25 | $1.21 | $0.86 | ||
| Q3 25 | $1.25 | $0.40 | ||
| Q2 25 | $1.14 | $0.46 | ||
| Q1 25 | $1.26 | $0.35 | ||
| Q4 24 | $3.20 | $0.77 | ||
| Q3 24 | $2.59 | $0.77 | ||
| Q2 24 | $2.61 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $78.2M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.6B | $7.3B |
| 总资产 | $4.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCSRVTY
| Q1 26 | $78.2M | — | ||
| Q4 25 | $109.4M | $919.9M | ||
| Q3 25 | $130.1M | $931.4M | ||
| Q2 25 | $93.2M | $991.8M | ||
| Q1 25 | $100.3M | $1.1B | ||
| Q4 24 | $150.0M | $1.2B | ||
| Q3 24 | $149.2M | $1.2B | ||
| Q2 24 | $106.7M | $2.0B |
股东权益CCSRVTY
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $7.3B | ||
| Q3 25 | $2.6B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.6B | $7.6B | ||
| Q4 24 | $2.6B | $7.7B | ||
| Q3 24 | $2.5B | $7.9B | ||
| Q2 24 | $2.5B | $7.9B |
总资产CCSRVTY
| Q1 26 | $4.5B | — | ||
| Q4 25 | $4.5B | $12.2B | ||
| Q3 25 | $4.7B | $12.1B | ||
| Q2 25 | $4.6B | $12.4B | ||
| Q1 25 | $4.6B | $12.4B | ||
| Q4 24 | $4.5B | $12.4B | ||
| Q3 24 | $4.8B | $12.8B | ||
| Q2 24 | $4.3B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流CCSRVTY
| Q1 26 | — | — | ||
| Q4 25 | $210.7M | $182.0M | ||
| Q3 25 | $-10.0M | $138.5M | ||
| Q2 25 | $-11.0M | $134.3M | ||
| Q1 25 | $-36.6M | $128.2M | ||
| Q4 24 | $299.7M | $174.2M | ||
| Q3 24 | $-95.5M | $147.9M | ||
| Q2 24 | $-100.1M | $158.6M |
自由现金流CCSRVTY
| Q1 26 | — | — | ||
| Q4 25 | $202.6M | $161.8M | ||
| Q3 25 | $-20.8M | $120.0M | ||
| Q2 25 | $-17.6M | $115.5M | ||
| Q1 25 | $-40.0M | $112.2M | ||
| Q4 24 | $290.6M | $149.8M | ||
| Q3 24 | $-101.9M | $125.6M | ||
| Q2 24 | $-117.6M | $136.6M |
自由现金流率CCSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | 21.0% | ||
| Q3 25 | -2.1% | 17.2% | ||
| Q2 25 | -1.8% | 16.0% | ||
| Q1 25 | -4.4% | 16.9% | ||
| Q4 24 | 22.8% | 20.5% | ||
| Q3 24 | -9.0% | 18.4% | ||
| Q2 24 | -11.3% | 19.7% |
资本支出强度CCSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 0.7% | 2.6% | ||
| Q1 25 | 0.4% | 2.4% | ||
| Q4 24 | 0.7% | 3.4% | ||
| Q3 24 | 0.6% | 3.3% | ||
| Q2 24 | 1.7% | 3.2% |
现金转化率CCSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 5.86× | 1.85× | ||
| Q3 25 | -0.27× | 2.97× | ||
| Q2 25 | -0.32× | 2.49× | ||
| Q1 25 | -0.93× | 3.03× | ||
| Q4 24 | 2.92× | 1.84× | ||
| Q3 24 | -1.15× | 1.57× | ||
| Q2 24 | -1.20× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCS
| Home sales revenues | $734.1M | 93% |
| Land sales and other revenues | $33.2M | 4% |
| Financial services revenues | $22.4M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
